A systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what’s on the label what’s in the product?
- Resource Type
- Authors
- Stacey M. Kung; Marjan Doppen; Giles Newton-Howes; Karen Oldfield; Irene Braithwaite; John Ryan
- Source
- Australasian Psychiatry. 29:88-96
- Subject
- Cannabinoids
medicine.medical_treatment
010401 analytical chemistry
01 natural sciences
0104 chemical sciences
03 medical and health sciences
Psychiatry and Mental health
0302 clinical medicine
Labelling
medicine
Humans
030212 general & internal medicine
Business
Biochemical engineering
Cannabinoid
Product (category theory)
- Language
- ISSN
- 1440-1665
1039-8562
Objectives: To review the literature regarding label accuracy and contamination of medical cannabinoid-based products. Methods: A systematic review with meta-analysis following PRISMA guidelines. This study is registered with PROSPERO (CRD42019131565). Results: Five studies reported label accuracy data ranging between 17% and 86%. Four studies reported contaminants, including pesticides, solvents and AB-FUBINACA. Meta-analysis was limited to the proportion of pesticide-contaminated samples found in two studies (0.25 (95% CI [0.10, 0.40])) and displayed significant heterogeneity. Conclusions: Label inaccuracies and contaminants are found across a spectrum of cannabinoid-based products. The review highlights the paucity and heterogeneity of research relating to cannabinoid-based products in light of changing global legislation. Further robust research is required to support ongoing pharmacovigilance and patient safety.